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ABSTRACT 42 
 43 
Mutations in the genes of the F420 signaling pathway, including dnn, fgd1, fbiA, fbiB, fbiC, and fbiD, of 44 
Mycobacterium tuberculosis (Mtb) complex can lead to delamanid resistance. We searched for such 45 
mutations among 129 Mtb strains from Asia, South-America, and Africa using whole-genome 46 
sequencing; 70 (54%) strains had at least one mutation in one of the genes. For ten strains with 47 
mutations, we determined the minimum inhibitory concentration (MIC) of delamanid. We found one 48 
strain from a delamanid-naïve patient carrying the natural polymorphism Tyr29del (ddn) that was 49 
associated with a critical MIC to delamanid. 50 
 51 
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In 2014, the new anti-tuberculosis (TB) drug, delamanid (also known as OPC-67683 or Deltyba™) 59 
was introduced (1). The World Health Organisation (WHO) recommends the administration of 60 
delamanid if a standard effective drug regimen cannot be prescribed due to drug toxicity or resistance 61 
(2, 3). Thus, the European Medicines Agency (EMA) conditionally approved delamanid for the 62 
treatment of multidrug-resistant (MDR) TB (1, 3, 4). Of note, six years after its market launch, robust 63 
and widely accepted breakpoints that define susceptibility and resistance to delamanid still do not 64 
exist (5). The few available studies suggest a critical MIC between 0.125 mg/L and 0.2 mg/L, and an 65 
Epidemiological Cutoff Value (ECOFF) of 0.04 mg/L (6-9). This ECOFF is in line with the WHO (10).  66 
 67 
Delamanid is a drug of the bicyclic nitroimidazole class with potent anti-TB activity (1, 11). It is a pro-68 
drug which is activated by the deazaflavin (F420) dependent nitroreductase (ddn) through hydride 69 
transfer, forming unstable intermediates, which in turn lead to the formation of reactive nitrogen 70 
species (nitric oxide, nitrous acid) (12, 13). Activated delamanid thus has a dual bactericidal mode of 71 
action as the primary decomposition product prevents mycolic acid synthesis while the reactive 72 
nitrogen species cause respiratory poisoning (12-15). Loss of function mutations in ddn or one of the 73 
five coenzymes (fgd1, fbiA, fbiB, fbiC, and fbiD) have been proposed as a mechanism of resistance to 74 
delamanid (12, 13, 16, 17). In vitro, frequencies of delamanid resistance-conferring mutations in the 75 
Mycobacterium tuberculosis (Mtb) laboratory strain H37Rv and in M. bovis range from 2.51 × 10
−5
 to 76 
6.44 × 10
−6
 (13). Previous studies have found several resistance-conferring mutations, including 77 
Leu107Pro (ddn), 51-101del (ddn), Trp88STOP (ddn), Gly81Asp (ddn), Gly81Ser (ddn), Gly53Asp 78 
(ddn), c.146_147insC (fgd1), Gln88Glu (fgd1), Lys250STOP (fbiA), Arg175His (fbiA), and Val318Ile 79 
(fibC) (6-8, 18-22).   80 
 81 
This multicentre study has been described in detail elsewhere and is part of the International 82 
epidemiology Databases to Evaluate AIDS (IeDEA) (23). We identified putative delamanid resistance-83 
conferring mutations in Mtb strains from TB patients living with HIV (PLWH) and HIV negative TB 84 
patients naïve to delamanid using whole-genome sequencing (WGS) and MIC determination. We 85 
collected demographic and clinical characteristics of patients that were recruited between 2013-2016 86 
in Peru, Thailand, Côte d’Ivoire, Democratic Republic of the Congo (DRC), Kenya, and South Africa 87 
(24, 25). The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards 88 
approved the study. Written informed consent was obtained at all locations, except in South Africa, 89 
where consent was not required for archived samples. 90 
 91 
The sequencing pipeline has been described previously (25). In brief, Mtb DNA was extracted and 92 
sequenced using Illumina HiSeq 2500 (Illumina, San Diego, CA, USA). For the analysis, we used the 93 
well-established pipeline TBprofiler (https://github.com/jodyphelan/TBProfiler (26, 27)). It aligns short 94 
reads to the Mtb reference (H37Rv: NC_000962.3) with bowtie2 v2.3.5, BWA v0.7.17 or minimap2 95 
v2.16 and then calls variants with SAMtools v1.9 (28-31). To identify putative delamanid resistance-96 
conferring mutations, we analysed F420 genes (ddn, fgd1, fbiA, fbiB, fbiC, and fbiD) with variant 97 
frequencies ≥75%. A subset of Mtb strains with at least one mutation in F420 genes were re-cultured in 98 
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liquid medium and subjected to delamanid MIC determination (Supplementary Figure 1). We 99 
assumed that 0.04 mg/L indicates a critical MIC (9).  100 
 101 
We included 129 Mtb isolates among them 52 (40.3%) from Peru, 14 (10.9%) from Thailand, 51 102 
(39.5%) from Côte d’Ivoire, 14 (10.9%) from DRC, and 1 (0.8%) each from Kenya and South Africa. 103 
We identified 70 (54.3%) isolates with polymorphisms in at least one of the six F420 genes as 104 
compared to the reference genome (Supplementary Table 1). None of the patients infected with either 105 
of these strains had a history of TB and all were naïve to delamanid. We selected strains fulfilling the 106 
following criteria: i) mutations in a part of the gene encoding regions of catalytic or structural 107 
importance predicted by ARIBA and then the PhyResSE pipeline (32, 33), ii) culture of the strain 108 
available iii) bacterial growth amenable to microdilution (25). MIC determination was performed on ten 109 
isolates with mutations in the F420 genes. Four isolates showed a MIC >0.015 mg/L: 0.5 (patient 1), 110 
0.03 (patients 6 and 10), and >8 mg/L (patient 9; Table 1; Supplementary Figure 1). The isolate from 111 
patient 1 had a polymorphism in fgd1 (Lys270Met), was susceptible to the six tested drugs (isoniazid, 112 
rifampicin, ethambutol, pyrazinamide, moxifloxacin, and amikacin). The patient was cured. The isolate 113 
from patient 9 had two alterations, a deletion in ddn (Tyr29del) and carried a nucleotide change in 114 
fgd1 (T960C). The strain showed an elevated delamanid MIC and was phenotypically susceptible to 115 
six other drugs tested. The patient died. Isolates of patient 10 (and 6) had a MIC above 0.015 but 116 
below 0.04 mg/L (Table 1). This suggests a low-level resistance to delamanid (22), which could be 117 
due to the combination of various mutations: Ala416Val (fbiC), Trp678Gly (fbiC), Arg64Ser (fgd1), and 118 
T960C (fgd1). 119 
 120 
In summary, in the subset of ten isolates with polymorphisms in the six targeted genes, six had no 121 
elevated MIC in the microdultion, while four isolates had (Table 1).  In line with previous studies, we 122 
found that Lys270Met in fgd1 is a natural polymorphism characteristic of Mtb lineage 4.1.2.1, which 123 
may (patient 1 and 6) or may not (patient 7) lead to an increased delamanid MIC (19, 34, 35). All 16 124 
strains of lineage 4.1.2.1 showed this lineage-specific marker (Supplementary Table 1). Furthermore, 125 
T960C (fgd1) is a synonymous substitution and was found in three other patient isolates which 126 
expectedly did not have a critical MIC. The increase in the delamanid MIC in the isolate of patient 9 127 
was due to the deletion in ddn (7). Our results thus suggest that Tyr29del is a natural polymorphism 128 
leading to an increased delamanid MIC. Our study was too small to estimate the prevalence of strains 129 
that are naturally resistant to delamanid. Lee et al. 2020, screened 14,876 Mtb strains and found two 130 
strains with Tyr29del, for a prevalence of 0.013% (36). However, in their study, only the ddn gene was 131 
screened and the prevalence of natural resistance could, therefore, be higher. 132 
 133 
In conclusion, we confirm that mutations in F420 genes can confer an elevated delamanid MIC (13, 134 
19). Whether our findings also apply to the related drug pretomanid should be investigated in future 135 
studies. The occurrence of clinical Mtb isolates with naturally elevated MICs to delamanid from 136 
previously untreated patients calls for careful drug susceptibility testing (DST) prior to delamanid 137 
treatment (5, 36). However, access to DST is limited in high burden countries. This dilemma highlights 138 
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the conflict between making new drugs available in high-burden countries and avoiding spread of 139 
drug-resistant strains.  140 
 141 
Data availability. WGS data from patients Mtb strains shown in Table 1 have been submitted to the 142 
NCBI (PRJNA300846; Supplementary Table 1). 143 
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TABLE 1. Observed polymorphisms in F420 genes and minimal inhibitory concentration values for delamanid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: MIC, minimal inhibitory concentration; No, number; L, lineage; wt, wild-type; H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol. 
No. Lineage Country HIV 
status 
Age at 
TB 
diagnosis 
Gender Mutations in the F420 genes Treatment Treatment 
outcome 
MIC mg/L in 
the micro-
dilution 
0 H37Rv 
ATCC 
27294 
- - - - Control (wt) - - ≤0.015 
1 L4.1.2.1 Côte d'Ivoire Negative 29 Female fgd1 Lys270Met 2HRZE, 4RH Cured 0.5 
2 L4.6.2.2 Côte d'Ivoire Negative 51 Male ddn C168T 2HRZE, 4RH Died ≤0.015 
3 L2.2.1 Kenya Positive 40 Male fgd1 T960C 2HRZE, 4RH Died ≤0.015 
4 L2.2.1 Peru Positive 28 Male fgd1 T960C 2HRZE, 4RH Unknown ≤0.015 
5 L4.3.2 Peru Negative 21 Male fbiC C1161T  2HRZE, 4RH Cured ≤0.015 
6 L4.1.2.1 Peru Positive 45 Male fgd1 Lys270Met 2HRZE, 4RH Unknown 0.03 
7 L4.1.2.1 Peru Positive 36 Male fbiC G-11A 
fgd1 Lys270Met  
2HRZE, 4RH Unknown ≤0.015 
8 L4.1.2 South Africa Negative 57 Female fbiA Ile208Val  2HRZE, 4RH Cured ≤0.015 
9 L2.2.1 Thailand Unknown 76 Male fgd1 T960C  
ddn 85-87del (Tyr29del) 
2HRZE, 4RH Died >8 
10 L1.1.1 Thailand Negative 42 Male fbiC Ala416Val, Trp678Gly 
fgd1 Arg64Ser, T960C  
2HRZE, 4RH Unknown 0.03 
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